DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 149 filers reported holding DENALI THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $240,164 | +12.9% | 10,343 | -0.3% | 0.02% | +54.5% |
| Q1 2024 | $212,772 | -4.1% | 10,369 | +0.2% | 0.01% | -26.7% |
| Q4 2023 | $221,982 | +4.4% | 10,344 | +0.4% | 0.02% | +7.1% |
| Q3 2023 | $212,572 | -32.3% | 10,304 | -3.1% | 0.01% | -30.0% |
| Q2 2023 | $313,957 | +20.2% | 10,639 | -6.2% | 0.02% | +25.0% |
| Q1 2023 | $261,251 | +27.9% | 11,339 | +54.4% | 0.02% | +45.5% |
| Q4 2022 | $204,209 | -52.4% | 7,343 | -23.6% | 0.01% | 0.0% |
| Q4 2021 | $429,000 | +41.6% | 9,610 | +59.8% | 0.01% | +37.5% |
| Q3 2021 | $303,000 | -22.5% | 6,012 | +20.7% | 0.01% | -33.3% |
| Q2 2021 | $391,000 | +58.3% | 4,983 | +68.9% | 0.01% | +100.0% |
| Q4 2020 | $247,000 | -24.2% | 2,950 | -67.6% | 0.01% | -62.5% |
| Q3 2020 | $326,000 | +23.5% | 9,100 | -16.6% | 0.02% | +6.7% |
| Q2 2020 | $264,000 | +169.4% | 10,909 | +158.0% | 0.02% | +150.0% |
| Q1 2019 | $98,000 | +139.0% | 4,229 | +113.9% | 0.01% | +100.0% |
| Q4 2018 | $41,000 | – | 1,977 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |